Loading
A phase 1/2 trial of TT-10 in renal cell carcinoma, prostate cancer, non-small-cell lung cancer and mesothelioma, run by Portage Biotech, now recruiting.
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma is a phase 1/2 interventional study registered as NCT04969315 by Portage Biotech, with 35 participants planned, started 2023-06-23 and due to reach its primary completion in 2028-12-01. Interventions recorded: TT-10 and TT-4.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Renal cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Renal cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Prostate cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/